p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting

被引:29
作者
Borre, M [1 ]
Stausbol-Gron, B
Overgaard, J
机构
[1] Aarhus Univ Hosp, Danish Canc Soc, Dept Expt Clin Oncol, Aarhus, Denmark
[2] Aarhus Univ Hosp, Danish Canc Soc, Dept Urol, Aarhus, Denmark
关键词
genes; p53; bcl-2; tumor markers; biological; prostatic neoplasms; prostate;
D O I
10.1016/S0022-5347(05)67288-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We describe the association of p53 nuclear protein accumulation with bcl-2 expression, tumor cell proliferation and clinical outcome in a prostate cancer population undergoing watchful waiting. Materials and Methods: Immunohistochemical staining for p53 was semiquantitatively scored in archival formalin fixed, paraffin embedded tumor tissue obtained at diagnosis in 221 patients with prostate cancer. At a median of 15 years followup was nearly complete. Eventually 57% of the patients died of prostate cancer. Results: p53 Immunohistochemical staining was heterogeneous but in all cases at least clusters of tumor cells had nuclear staining for p53. The percent of p53 immunoreactive tumor cells was scored as 0 to 4+ in p53 positive hot spots, p53 immunoreactivity correlated with clinical stage and histopathological grade (p = 0.003 and 0.009, respectively). When dichotomized into low (0% to 50%) and high (51% to 100%) immunoreactivity groups of 40 and 181 patients, respectively, p53 accumulation was significantly associated with disease specific survival in the study population overall (p <0.0001) and in the 125 with clinically localized disease (p = 0.0002). p53 Immunoreactivity was significantly (p <0.001) associated with the proliferation marker MIB-1 (median value 10.3, range 0 to 46.1) but insignificantly (p = 0.8) correlated with bcl-2 expression (52% positive). However, patients with combined favorable MIB-1 and bcl-2 status were stratified into significant (p = 0.02) prognostic groups by p53 immunohistochemical status. Multivariate analysis revealed that p53 immunoreactivity was a significant prognostic factor in patients with clinically localized prostate cancer (p <0.0001). Conclusions: p53 Nuclear protein accumulation detected by immunohistochemical study was an independent adverse prognostic factor in patients with prostate cancer undergoing watchful waiting.
引用
收藏
页码:716 / 721
页数:6
相关论文
共 53 条
[1]   bcl-2 Overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer [J].
Apakama, I ;
Robinson, MC ;
Walter, NM ;
Charlton, RG ;
Royds, JA ;
Fuller, CE ;
Neal, DE ;
Hamdy, FC .
BRITISH JOURNAL OF CANCER, 1996, 74 (08) :1258-1262
[2]  
BARTEK J, 1991, ONCOGENE, V6, P1699
[3]  
Bauer JJ, 1995, CLIN CANCER RES, V1, P1295
[4]   Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer [J].
Bauer, JJ ;
Sesterhenn, IA ;
Mostofi, FK ;
McLeod, DG ;
Srivastava, S ;
Moul, JW .
JOURNAL OF UROLOGY, 1996, 156 (04) :1511-1516
[5]   PROSTATIC-CARCINOMA - A MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS [J].
BERNER, A ;
HARVEI, S ;
TRETLI, S ;
FOSSA, SD ;
NESLAND, JM .
BRITISH JOURNAL OF CANCER, 1994, 69 (05) :924-930
[6]   The dilemma of prostate cancer - A growing human and economic burden irrespective of treatment strategies [J].
Borre, M ;
Nerstrom, B ;
Overgaard, J .
ACTA ONCOLOGICA, 1997, 36 (07) :681-687
[7]  
Borre M, 1997, CANCER, V80, P917
[8]   Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly [J].
Borre, M ;
Strausbol-Gron, B ;
Nerstrom, B ;
Overgaard, J .
PROSTATE CANCER AND PROSTATIC DISEASES, 1998, 1 (05) :268-275
[9]   Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting [J].
Borre, M ;
Offersen, BV ;
Nerstrom, B ;
Overgaard, J .
BRITISH JOURNAL OF CANCER, 1998, 78 (07) :940-944
[10]   Tumor cell proliferation and survival in patients with prostate cancer followed expectantly [J].
Borre, M ;
Bentzen, SM ;
Nerstrom, B ;
Overgaard, J .
JOURNAL OF UROLOGY, 1998, 159 (05) :1609-1614